Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-997-2400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$15.09 million
Profitability
Miscellaneous
Employees152
Next Earnings Date11/8/2019 (Estimated)
OptionableOptionable
Adamis Pharmaceuticals (NASDAQ:ADMP) Frequently Asked Questions
What is Adamis Pharmaceuticals' stock symbol?
Adamis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMP."
How were Adamis Pharmaceuticals' earnings last quarter?
Adamis Pharmaceuticals Corp (NASDAQ:ADMP) posted its quarterly earnings results on Thursday, August, 8th. The specialty pharmaceutical company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.03. The specialty pharmaceutical company had revenue of $5.77 million for the quarter, compared to the consensus estimate of $5.82 million. Adamis Pharmaceuticals had a negative return on equity of 86.04% and a negative net margin of 205.32%. View Adamis Pharmaceuticals' Earnings History.
When is Adamis Pharmaceuticals' next earnings date?
What price target have analysts set for ADMP?
5 equities research analysts have issued twelve-month price objectives for Adamis Pharmaceuticals' stock. Their predictions range from $1.10 to $7.00. On average, they anticipate Adamis Pharmaceuticals' share price to reach $4.5250 in the next twelve months. This suggests a possible upside of 369.9% from the stock's current price. View Analyst Price Targets for Adamis Pharmaceuticals.
What is the consensus analysts' recommendation for Adamis Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamis Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Adamis Pharmaceuticals.
What are Wall Street analysts saying about Adamis Pharmaceuticals stock?
Here are some recent quotes from research analysts about Adamis Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged engages in the research, development, and commercialization of prescription medicines for the treatment of viral infections. Adamis Pharmaceuticals is composed of two wholly owned subsidiaries, Adamis Labs and Adamis Viral Therapies. Adamis Labs is a commercial stage specialty pharmaceutical company targeting high-prescribing physicians in the allergy, respiratory and pediatric medicine market segments. To complement and add to the sales efforts of Adamis Labs, Adamis Viral Therapies is focused on the development of patented, highly-valued proprietary vaccine technology that Adamis believes has the potential to prevent or treat infections such as influenza or chronic hepatitis. Adamis also provides packaging for pharmaceutical and nutraceutical products. The company is headquartered in Del Mar, California. " (8/13/2019)
- 2. Maxim Group analysts commented, "The PDUFA date for Symjepi jr. (0.15mg) is approaching on 9/27/18, we expect a positive response from the FDA. Symjepi (0.3mg & 0.15mg) is partnered to Sandoz-Novartis (NVS – NR). Our expectation is that Sandoz will launch both Symjepi products sometime in the second half following low-dose approval (though precise timing has not been announced)." (9/12/2018)
Has Adamis Pharmaceuticals been receiving favorable news coverage?
Press coverage about ADMP stock has trended positive recently, according to InfoTrie. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Adamis Pharmaceuticals earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned news headlines about the specialty pharmaceutical company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the near term. View News Stories for Adamis Pharmaceuticals.
Who are some of Adamis Pharmaceuticals' key competitors?
Some companies that are related to Adamis Pharmaceuticals include TapImmune (MRKR), Verrica Pharmaceuticals (VRCA), Aeglea Bio Therapeutics (AGLE), Xenon Pharmaceuticals (XENE), Ardelyx (ARDX), ProMetic Life Sciences (PFSCF), Evelo Biosciences (EVLO), Kamada (KMDA), Chiasma (CHMA), Forty Seven (FTSV), Ocular Therapeutix (OCUL), Five Prime Therapeutics (FPRX), Calithera Biosciences (CALA), Athersys (ATHX) and MannKind (MNKD).
What other stocks do shareholders of Adamis Pharmaceuticals own?
Who are Adamis Pharmaceuticals' key executives?
Adamis Pharmaceuticals' management team includes the folowing people:
- Mr. Richard C. Williams, Chairman & Consultant (Age 75)
- Dr. Dennis J. Carlo, Pres, CEO & Director (Age 76)
- Mr. Robert O. Hopkins, VP of Fin., CFO & Sec. (Age 59)
- Mr. David J. Marguglio, Sr. VP, Chief Bus. Officer & Director (Age 49)
- Mr. Robert B. Rothermel, Consultant & Director (Age 75)
Who are Adamis Pharmaceuticals' major shareholders?
Adamis Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.76%), First Manhattan Co. (2.27%), BlackRock Inc. (2.02%), Morgan Stanley (1.59%), GSA Capital Partners LLP (0.29%) and A.R.T. Advisors LLC (0.13%). Company insiders that own Adamis Pharmaceuticals stock include David J Marguglio, Dennis J Phd Carlo, Karen K Daniels, Robert B Rothermel, Robert O Hopkins and Ronald B Moss. View Institutional Ownership Trends for Adamis Pharmaceuticals.
Which institutional investors are selling Adamis Pharmaceuticals stock?
ADMP stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co. and Leisure Capital Management. Company insiders that have sold Adamis Pharmaceuticals company stock in the last year include David J Marguglio, Dennis J Phd Carlo, Karen K Daniels, Robert O Hopkins and Ronald B Moss. View Insider Buying and Selling for Adamis Pharmaceuticals.
Which institutional investors are buying Adamis Pharmaceuticals stock?
How do I buy shares of Adamis Pharmaceuticals?
Shares of ADMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Adamis Pharmaceuticals' stock price today?
One share of ADMP stock can currently be purchased for approximately $0.9630.
How big of a company is Adamis Pharmaceuticals?
Adamis Pharmaceuticals has a market capitalization of $59.16 million and generates $15.09 million in revenue each year. The specialty pharmaceutical company earns $-39,010,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. Adamis Pharmaceuticals employs 152 workers across the globe.View Additional Information About Adamis Pharmaceuticals.
What is Adamis Pharmaceuticals' official website?
How can I contact Adamis Pharmaceuticals?
Adamis Pharmaceuticals' mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The specialty pharmaceutical company can be reached via phone at 858-997-2400 or via email at [email protected]
MarketBeat Community Rating for Adamis Pharmaceuticals (NASDAQ ADMP)
MarketBeat's community ratings are surveys of what our community members think about Adamis Pharmaceuticals and other stocks. Vote "Outperform" if you believe ADMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
